FGFR-IN-23
FGFR-IN-23 (Compound 9p) is a covalent pan FGFR inhibitor with IC50s of 14, 4.2, 5 and 220 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-23 also has potent inhibitory activity against gatekeeper mutants, such as FGFR1V561M and FGFR3V555M. FGFR-IN-23 suppresses the activation of FGFR-mediated signaling and induces apoptosis. FGFR-IN-23 shows significant antitumor efficacy in RT112 xenograft mouse models. FGFR-IN-23 can be used for cancers and its drug resistance research[1].
Product Specifications
UNSPSC
12352005
Target
Akt; Apoptosis; ERK; FGFR; p38 MAPK
Related Pathways
Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
C=CC(NC1=CC2=C(C=C1)C(C3=CNC4=NC=C(C5=CN(CCN6CCOCC6)N=C5)N=C43)=CN2C)=O
Molecular Formula
C27H28N8O2
Molecular Weight
496.56
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
FGFR1; FGFR2; FGFR3; FGFR4
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1997R), CF740 conjugate, 0.1mg/mL
